Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News BMS confirms ‘improved survival’ in Erbitux trial

BMS confirms ‘improved survival’ in Erbitux trial

15th November 2007

Bristol Myers Squibb (BMS) and ImClone Systems have confirmed that Erbitux (cetuximab) has demonstrated a significant improvement in overall survival in patients with metastatic colorectal cancer (mCRC) refractory compared to other approved chemotherapy agents.

Data was drawn from a Phase III trial with the results published in the New England Journal of Medicine Study.

Treatment using Erbitux alongside best supportive care was compared with BSC alone in patients with mCRC whose disease had progressed through chemotherapy treatments including irinotecan, oxaliplatin and fluoropyrimidines.

It was found that treating patients with Erbitux as a monotherapy plus BSC significantly improved survival compared to BSC alone.

Maurizio Voi, executive director of oncology global medical affairs at Bristol Myers Squibb, described how the results were part of a comprehensive clinical development programme which intended to assess the potential uses of Erbitux.

“This data demonstrates that Erbitux may provide certain colorectal cancer patients with additional time – even when other available treatment options have failed.”

Last month, BMS and Imclone Systems received US Food and Drug Administration approval for an update to labelling for Erbitux.

The data in this trial was used in the label update which now displays overall survival data when used in the treatment of epidermal growth factor inhibitor-expressing mCRC patients after failure of both irinotecan and oxaliplatin-based regimens.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.